

Supplemental Table 1. Baseline characteristics for progressors and nonprogressors at week 104.

Baseline characteristics	Golimumab 50 mg + MTX		Golimumab 100 mg + MTX	
	Patients with change in total vdH-S \geq 3 (n=54)	Patients with change in total vdH-S < 3 (n=13)	Patients with change in total vdH-S \geq 3 (n=57)	Patients with change in total vdH-S < 3 (n=14)
Disease				
duration, years	9.5 (9.4)	3.8 (3.5)*	8.1 (6.5)	6.0 (5.2)
DAS28-ESR	5.2 (1.1)	6.4 (0.7)*	5.4 (1.0)	5.8 (1.0)
TJC	12.2 (7.8)	16.4 (8.6)	12.9 (7.3)	15.1 (10.5)
SJC	10.4 (5.9)	15.9 (6.6)*	11.2 (6.4)	13.9 (7.6)
HAQ-DI	0.9 (0.6)	1.1 (0.6)	1.0 (0.6)	1.0 (0.6)
CRP	1.2 (1.2)	3.4 (3.0)*	1.3 (1.4)	2.6 (2.4)*
vdH-S	54.2 (62.0)	42.6 (45.7)	53.7 (49.8)	41.8 (33.0)
Annual rate of radiographic progression ^a	6.7 (6.7)	11.1 (6.5)*	7.4 (5.6)	12.3 (14.0)*

Data presented as mean (SD). ^avdH-S/disease duration *p<0.05

CRP, C-reactive protein; DAS28-ESR, 28-joint count Disease Activity Score using erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire-Disability Index; MTX, methotrexate; SJC, swollen joint count; TJC, tender joint count; vdH-S score, van der Heijde modification of the Sharp score